HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prop 65

This article was originally published in The Rose Sheet

Executive Summary

California Office of Environmental Health Hazard Assessment plans to establish a "no observable effect" level for di(2-ethylhexyl) phthalate, agency announces. For chemicals listed on Prop 65 as known to the state to cause cancer, a warning label is required on products unless a manufacturer is able to demonstrate that exposure to the product causes no reproducible observable effect, assuming exposure levels 1,000 times those in question. Hearing on the no observable effect level for DEHP will be held Dec. 13 in Sacramento, Calif. Comments will be accepted until then...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012555

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel